Mira Pharmaceuticals is focused on developing innovative therapies, particularly the next generation of oral ketamine and pharmaceutical marijuana analogs, aimed at treating neurologic and neuropsychiatric disorders. Their approach emphasizes making small modifications to existing compounds, which can lead to significant improvements in therapeutic outcomes. This strategy not only seeks to enhance the efficacy of treatments but also aims to expand the market for various indications and patient populations, thereby redefining the landscape of available therapies.

The company is advancing its research through products like MIRA-55 and Ketamir, which are positioned within a robust pipeline of clinical trials. Their commitment to scientific rigor is reflected in their detailed research publications and the structured design of their clinical trial protocols, including the recent Phase I/IIa studies. By leveraging these technologies, Mira Pharmaceuticals aims to deliver improved therapeutic options that could potentially transform the treatment paradigm for patients suffering from complex neurological and psychiatric conditions.

United States

MIRA1a is being developed to treat anxiety and cognitive decline in the elderly and neuropathic pain without impurities or the adverse side effects of cannabis plant extracts.

Nervous System Diseases

Psychological Diseases

Mira Pharmaceuticals

Acute Suicidal Ideation and Behavior

Major depressive disorder

Mental health

Neuropathic pain

Post-traumatic stress disorder

Treatment Resistant Depression

<p class="font_8">A Novel Oral Ketamine Analog.</p>

Ketamir-2

Anxiety

Dementia

MIRA1A

Small Molecule Pharmaceuticals

Maryland

Marijuana/Cannabinoid-Derived Drugs

Therapeutic

Mira Pharmaceuticals

Company Details